146 related articles for article (PubMed ID: 36394112)
1. A survey of mechanisms underlying current and potential COVID-19 vaccines.
Hebel C; Thomsen AR
APMIS; 2023 Feb; 131(2):37-60. PubMed ID: 36394112
[TBL] [Abstract][Full Text] [Related]
2. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
Jafari A; Danesh Pouya F; Niknam Z; Abdollahpour-Alitappeh M; Rezaei-Tavirani M; Rasmi Y
Mol Biol Rep; 2022 Jun; 49(6):4943-4957. PubMed ID: 35235159
[TBL] [Abstract][Full Text] [Related]
3. Super-rapid race for saving lives by developing COVID-19 vaccines.
Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A
J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582
[TBL] [Abstract][Full Text] [Related]
4. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.
Khoshnood S; Arshadi M; Akrami S; Koupaei M; Ghahramanpour H; Shariati A; Sadeghifard N; Heidary M
J Clin Lab Anal; 2022 May; 36(5):e24418. PubMed ID: 35421266
[TBL] [Abstract][Full Text] [Related]
5. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
6. [Vaccination contre le SARS-CoV-2, le Graal ?].
Binh Luong Nguyen L; Lachâtre M; Launay O
Rev Prat; 2022 May; 72(5):517-522. PubMed ID: 35899638
[TBL] [Abstract][Full Text] [Related]
7. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
8. Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?
Joshi G; Borah P; Thakur S; Sharma P; Mayank ; Poduri R
Hum Vaccin Immunother; 2021 Dec; 17(12):4714-4740. PubMed ID: 34856868
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 vaccine candidates in rapid development.
Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
[TBL] [Abstract][Full Text] [Related]
11. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.
Malik JA; Ahmed S; Mir A; Shinde M; Bender O; Alshammari F; Ansari M; Anwar S
J Infect Public Health; 2022 Feb; 15(2):228-240. PubMed ID: 35042059
[TBL] [Abstract][Full Text] [Related]
12. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
[TBL] [Abstract][Full Text] [Related]
13. Vaccine Against Covid-19 Disease - Present Status of Development.
Dutta AK
Indian J Pediatr; 2020 Oct; 87(10):810-816. PubMed ID: 32880819
[TBL] [Abstract][Full Text] [Related]
14. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
15. Biological composition, efficacy and primary efficacy endpoint of SARS-CoV-2 vaccines: A special communication.
Ishaque I; Muhib M; Khalid Jamil OB
J Pak Med Assoc; 2022 Nov; 72(11):2264-2269. PubMed ID: 37013299
[TBL] [Abstract][Full Text] [Related]
16. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development.
Calina D; Sarkar C; Arsene AL; Salehi B; Docea AO; Mondal M; Islam MT; Zali A; Sharifi-Rad J
Immunol Res; 2020 Dec; 68(6):315-324. PubMed ID: 33006053
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
18. Status of COVID-19 vaccine development.
Taxt AM; Grødeland G; Lind A; Müller F
Tidsskr Nor Laegeforen; 2020 Sep; 140(13):. PubMed ID: 32998488
[TBL] [Abstract][Full Text] [Related]
19. mRNA Vaccines in the COVID-19 Pandemic and Beyond.
Hogan MJ; Pardi N
Annu Rev Med; 2022 Jan; 73():17-39. PubMed ID: 34669432
[TBL] [Abstract][Full Text] [Related]
20. A review of the safety and efficacy of current COVID-19 vaccines.
Huang Z; Su Y; Zhang T; Xia N
Front Med; 2022 Feb; 16(1):39-55. PubMed ID: 35122210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
